Salute e Benessere
BIOVAXYS ANNOUNCES PRIVATE PLACEMENT OFFERING
Each Unit consists of one (1) common share in the capital of the Company (each, a " ") and one (1) whole Share purchase warrant (each, a " "), whereby each Warrant shall be convertible into an additional Share at an exercise price of $0.15 for a period of 24 months from the date of issuance.
The Company intends to use the net proceeds raised from the Offering for working capital and may pay finder's fees related to the Offering.
All securities issued pursuant to the Offering will be subject to a hold period expiring four months and one day from the date of issuance in accordance with applicable securities laws. The closing of the Offering is subject to the receipt of all necessary regulatory approvals, including the approval of the Canadian Securities Exchange.
This news release does not constitute an offer to sell or a solicitation of an offer to buy of any securities in the United States . The securities issued have not been registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the " "), or any state securities laws, and may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to available exemptions therefrom.
BioVaxys Technology Corp. ( www.biovaxys.com ), a company registered in British Columbia, Canada , is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it's HapTenix© 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. DPX™ is a patented antigen delivery platform that can incorporate a range of bioactive molecules to produce targeted, long-lasting immune responses enabled by various formulated components. The DPX platform facilitates antigen delivery to regional lymph nodes and has been demonstrated to induce robust and durable T cell and B cell responses in pre-clinical and clinical studies for both cancer and infectious disease. BioVaxys' common shares are listed on the Canadian Securities Exchange under the stock symbol "BIOV", on the Frankfurt Bourse (FRA: 5LB), and quoted in the US on the OTC Markets. For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.
Signed " "
James Passin , Chief Executive Officer
Phone: +1 740 358 0555
View original content: https://www.prnewswire.co.uk/news-releases/biovaxys-announces-private-placement-offering-302309154.html